Ocular Therapeutix (OCUL) Misses Q4 EPS by 5c

Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.35), $0.05 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $14.8 million versus the consensus estimate of $15.87 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Activist investor presses Xerox to review financial services arm - Bloomberg
• ServiceTitan, Inc. (TTAN) Misses Q2 EPS by 1c, Offers Guidance
• Mission Produce (AVO) Misses Q3 EPS by 2c; offers outlook